We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Urology

Journal Scan / Research · July 29, 2021

Combined High-Dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer

European Urology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-Dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer
Eur Urol 2021 Jul 08;[EPub Ahead of Print], S Supiot, L Vaugier, D Pasquier, X Buthaud, N Magné, D Peiffert, P Sargos, G Crehange, P Pommier, G Loos, A Hasbini, I Latorzeff, M Silva, F Denis, JL Lagrange, C Morvan, L Campion, A Blanc-Lapierre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading